Tiantan Biological's general counsel Ci Xiang departs for new role

Beijing Tiantan Biological Products Corporation has received a resignation report from Ci Xiang, its general counsel and chief compliance officer, effective September 28, 2025. Ci Xiang's departure is due to a job transfer, occurring ahead of her original term end date of May 24, 2026. She will, however, continue to serve as a director for the company's subsidiary, Sinopharm Group Xi'an Biological Pharmaceutical Co., Ltd., until a new director is elected due to the subsidiary's board membership falling below the statutory minimum.

As of the announcement date, Ci Xiang directly holds 24,000 shares of Beijing Tiantan Biological Products Corporation, representing 0.0012% of the total share capital. She has pledged to adhere to her commitment, disclosed on August 30, 2023, not to reduce her shareholding within the statutory period, as outlined in the "Announcement on the Shareholding Increase Plan for Directors, Supervisors, and Senior Management Personnel."

The company confirmed that Ci Xiang's departure will not impact its normal operations. Beijing Tiantan Biological Products Corporation expressed its sincere gratitude for her contributions over the years.